Pharmaceuticals News and Research

RSS

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye.

1 Dec 2014

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).

1 Dec 2014

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again.

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Valeant to redeem US$445.0M aggregate principal amount of 6.875% Senior Notes due 2018

Valeant Pharmaceuticals International, Inc. today announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem US$445.0 million aggregate principal amount of its outstanding 6.875% Senior Notes due 2018, CUSIP Nos. 91911XAN4, U9098VAF9 (the "Notes") on December 29, 2014 and has mailed an irrevocable notice of redemption for the Notes.

29 Nov 2014

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014.

29 Nov 2014

New active substance effectively combats Philadelphia chromosome-positive leukaemia

Haematologists from Goethe University Frankfurt, working with a Russian pharmaceutical company, have developed a new active substance that effectively combats the most aggressive forms of Philadelphia chromosome-positive leukaemia.

29 Nov 2014

Lord Saatchi's Medical Innovation Bill may cause serious harm to patients

The Medical Innovation Bill tabled by Lord Saatchi and currently making its way through the UK’s House of Lords “strikes at the heart of evidence-based medicine” and risks “opening the door to the use of less proven, or unproven, approaches such as complementary or alternative medicine”, according to a new Editorial published in The Lancet Oncology.

29 Nov 2014

Researchers investigate FDA influence for improving pivotal drug studies

An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome, according to a study in the November 26 issue of JAMA.

28 Nov 2014

Hovione submits first IND Application with FDA for minocycline gel

Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs.

27 Nov 2014

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.

27 Nov 2014

FDA issues Complete Response letter for Avanir’s AVP-825 NDA

Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for AVP-825.

27 Nov 2014

Researchers use EHRs to uncover hidden drug benefits

With research and development costs for many drugs reaching well into the billions, pharmaceutical companies want more than ever to determine whether their drugs already at market have any hidden therapeutic benefits that could warrant putting additional indications on the label and increase production.

27 Nov 2014

Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want to know why this research isn't more widely used.

27 Nov 2014

Researchers set up innovative project to monitor physical activity of patients with haemophilia

The research group Intelligent Data Analysis Laboratory from the School of Engineering Universitat de València (UV) and a team of scientists at the Faculty of Physiotherapy led by Professor Felipe Querol have set up an innovative project for monitoring the physical activity of people with haemophilia through individual devices with the purpose of developing patterns which help to improve their quality of life and treatments.

26 Nov 2014

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital.

26 Nov 2014

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as electroCore’s non-invasive vagus nerve stimulation (nVNS).

26 Nov 2014

Nepstar revenue increases 8.1% to RMB738.3 million (US$120.3million) in Q3 2014

China Nepstar Chain Drugstore Ltd., a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2014.

26 Nov 2014

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Parent Project Muscular Dystrophy, the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne) and Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases, will collaborate on a benefit/risk study in Duchenne.

25 Nov 2014

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA).

25 Nov 2014

Pharmaceuticals News and Research

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Australian Prescriber publishes top 10 subsidised drugs in Australia

iCo Therapeutics announces corporate update and Q3 2014 financial results

Valeant to redeem US$445.0M aggregate principal amount of 6.875% Senior Notes due 2018

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

New active substance effectively combats Philadelphia chromosome-positive leukaemia

Lord Saatchi's Medical Innovation Bill may cause serious harm to patients

Researchers investigate FDA influence for improving pivotal drug studies

Hovione submits first IND Application with FDA for minocycline gel

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

FDA issues Complete Response letter for Avanir’s AVP-825 NDA

Researchers use EHRs to uncover hidden drug benefits

Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

Researchers set up innovative project to monitor physical activity of patients with haemophilia

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

Nepstar revenue increases 8.1% to RMB738.3 million (US$120.3million) in Q3 2014

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence